WO2010113590A1 - 美白剤及び皮膚を美白にする美容方法 - Google Patents
美白剤及び皮膚を美白にする美容方法 Download PDFInfo
- Publication number
- WO2010113590A1 WO2010113590A1 PCT/JP2010/053569 JP2010053569W WO2010113590A1 WO 2010113590 A1 WO2010113590 A1 WO 2010113590A1 JP 2010053569 W JP2010053569 W JP 2010053569W WO 2010113590 A1 WO2010113590 A1 WO 2010113590A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hydroxyproline
- cis
- ppm
- skin
- whitening
- Prior art date
Links
- 230000002087 whitening effect Effects 0.000 title claims abstract description 42
- 239000002537 cosmetic Substances 0.000 title claims abstract description 20
- 238000000034 method Methods 0.000 title claims abstract description 15
- 239000007854 depigmenting agent Substances 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 claims abstract description 115
- 150000003839 salts Chemical class 0.000 claims abstract description 23
- PMMYEEVYMWASQN-IMJSIDKUSA-N cis-4-Hydroxy-L-proline Chemical compound O[C@@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-IMJSIDKUSA-N 0.000 claims abstract description 21
- 150000001875 compounds Chemical class 0.000 claims abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 25
- 235000013305 food Nutrition 0.000 claims description 7
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 78
- 238000009472 formulation Methods 0.000 description 44
- 210000004027 cell Anatomy 0.000 description 39
- 235000002639 sodium chloride Nutrition 0.000 description 29
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- -1 4,4′-dimethyloxytrityl Chemical group 0.000 description 23
- 238000002156 mixing Methods 0.000 description 23
- 210000003491 skin Anatomy 0.000 description 20
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 238000013329 compounding Methods 0.000 description 16
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 14
- 235000011187 glycerol Nutrition 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- 239000008213 purified water Substances 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 11
- 230000036564 melanin content Effects 0.000 description 11
- 208000001382 Experimental Melanoma Diseases 0.000 description 10
- 230000010261 cell growth Effects 0.000 description 10
- 239000000284 extract Substances 0.000 description 10
- 239000000052 vinegar Substances 0.000 description 10
- 235000021419 vinegar Nutrition 0.000 description 10
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 9
- 230000004663 cell proliferation Effects 0.000 description 9
- 239000000443 aerosol Substances 0.000 description 8
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 8
- 235000013557 nattō Nutrition 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 235000013555 soy sauce Nutrition 0.000 description 8
- 235000000346 sugar Nutrition 0.000 description 8
- 229940058015 1,3-butylene glycol Drugs 0.000 description 7
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 7
- 229920002125 Sokalan® Polymers 0.000 description 7
- 235000019437 butane-1,3-diol Nutrition 0.000 description 7
- 239000004202 carbamide Substances 0.000 description 7
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000003205 fragrance Substances 0.000 description 7
- 229960002591 hydroxyproline Drugs 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 7
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 7
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 6
- XGDPKUKRQHHZTH-UHFFFAOYSA-N Methyl 2,5-dihydroxybenzoate Chemical compound COC(=O)C1=CC(O)=CC=C1O XGDPKUKRQHHZTH-UHFFFAOYSA-N 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 239000006210 lotion Substances 0.000 description 6
- 239000011259 mixed solution Substances 0.000 description 6
- 238000011002 quantification Methods 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 6
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 5
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 5
- 208000012641 Pigmentation disease Diseases 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 235000013312 flour Nutrition 0.000 description 5
- 230000001771 impaired effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000008099 melanin synthesis Effects 0.000 description 5
- 238000003359 percent control normalization Methods 0.000 description 5
- 229960002429 proline Drugs 0.000 description 5
- 229940042585 tocopherol acetate Drugs 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 4
- 235000002566 Capsicum Nutrition 0.000 description 4
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 4
- 240000008415 Lactuca sativa Species 0.000 description 4
- 235000015429 Mirabilis expansa Nutrition 0.000 description 4
- 244000294411 Mirabilis expansa Species 0.000 description 4
- 240000007594 Oryza sativa Species 0.000 description 4
- 235000007164 Oryza sativa Nutrition 0.000 description 4
- 239000006002 Pepper Substances 0.000 description 4
- 235000016761 Piper aduncum Nutrition 0.000 description 4
- 240000003889 Piper guineense Species 0.000 description 4
- 235000017804 Piper guineense Nutrition 0.000 description 4
- 235000008184 Piper nigrum Nutrition 0.000 description 4
- 239000004359 castor oil Substances 0.000 description 4
- 235000019438 castor oil Nutrition 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 235000014510 cooky Nutrition 0.000 description 4
- 239000004205 dimethyl polysiloxane Substances 0.000 description 4
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 4
- 229960000735 docosanol Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 210000002752 melanocyte Anatomy 0.000 description 4
- 235000013536 miso Nutrition 0.000 description 4
- 239000002304 perfume Substances 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- 235000009566 rice Nutrition 0.000 description 4
- 235000012045 salad Nutrition 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 239000004386 Erythritol Substances 0.000 description 3
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- 239000002211 L-ascorbic acid Substances 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229940087168 alpha tocopherol Drugs 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 235000008429 bread Nutrition 0.000 description 3
- 229940008396 carrot extract Drugs 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 229940009714 erythritol Drugs 0.000 description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 3
- 235000019414 erythritol Nutrition 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 235000011194 food seasoning agent Nutrition 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 239000008268 mayonnaise Substances 0.000 description 3
- 235000010746 mayonnaise Nutrition 0.000 description 3
- 229960005323 phenoxyethanol Drugs 0.000 description 3
- 230000019612 pigmentation Effects 0.000 description 3
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 3
- 229910000160 potassium phosphate Inorganic materials 0.000 description 3
- 235000011009 potassium phosphates Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 229960000984 tocofersolan Drugs 0.000 description 3
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 3
- 235000013618 yogurt Nutrition 0.000 description 3
- 239000002076 α-tocopherol Substances 0.000 description 3
- 235000004835 α-tocopherol Nutrition 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 2
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 2
- ASKIVFGGGGIGKH-UHFFFAOYSA-N 2,3-dihydroxypropyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(O)CO ASKIVFGGGGIGKH-UHFFFAOYSA-N 0.000 description 2
- 244000247812 Amorphophallus rivieri Species 0.000 description 2
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- 241000208688 Eucommia Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229920002752 Konjac Polymers 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 229930182821 L-proline Natural products 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 2
- 240000000912 Macadamia tetraphylla Species 0.000 description 2
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 2
- 206010027145 Melanocytic naevus Diseases 0.000 description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 2
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical compound CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229940106189 ceramide Drugs 0.000 description 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- 229940110767 coenzyme Q10 Drugs 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- 210000002969 egg yolk Anatomy 0.000 description 2
- 210000001339 epidermal cell Anatomy 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000021552 granulated sugar Nutrition 0.000 description 2
- XJNUECKWDBNFJV-UHFFFAOYSA-N hexadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC XJNUECKWDBNFJV-UHFFFAOYSA-N 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 238000005470 impregnation Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229940119170 jojoba wax Drugs 0.000 description 2
- 239000000252 konjac Substances 0.000 description 2
- 235000010485 konjac Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019136 lipoic acid Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 230000003505 mutagenic effect Effects 0.000 description 2
- 231100000243 mutagenic effect Toxicity 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 2
- 239000010466 nut oil Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 229940109850 royal jelly Drugs 0.000 description 2
- 235000015067 sauces Nutrition 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 229940037001 sodium edetate Drugs 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 229960002663 thioctic acid Drugs 0.000 description 2
- PMMYEEVYMWASQN-IUYQGCFVSA-N trans-4-hydroxy-D-proline Chemical compound O[C@@H]1CN[C@@H](C(O)=O)C1 PMMYEEVYMWASQN-IUYQGCFVSA-N 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 235000019158 vitamin B6 Nutrition 0.000 description 2
- 239000011726 vitamin B6 Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 1
- HOVAGTYPODGVJG-UVSYOFPXSA-N (3s,5r)-2-(hydroxymethyl)-6-methoxyoxane-3,4,5-triol Chemical compound COC1OC(CO)[C@@H](O)C(O)[C@H]1O HOVAGTYPODGVJG-UVSYOFPXSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 1
- NDHNBHXAALUAAJ-UHFFFAOYSA-N 4,5-dimorpholin-4-yl-1h-pyridazin-6-one Chemical compound C1COCCN1C=1C(O)=NN=CC=1N1CCOCC1 NDHNBHXAALUAAJ-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- NRBBRYPERXZHLD-UHFFFAOYSA-N COC1=C(C(=C(C(=O)OO[Si](C)(C)C)OC)OC)C=CC=C1 Chemical compound COC1=C(C(=C(C(=O)OO[Si](C)(C)C)OC)OC)C=CC=C1 NRBBRYPERXZHLD-UHFFFAOYSA-N 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- IUMSDRXLFWAGNT-UHFFFAOYSA-N Dodecamethylcyclohexasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 IUMSDRXLFWAGNT-UHFFFAOYSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000000421 Lepidium meyenii Nutrition 0.000 description 1
- 240000000759 Lepidium meyenii Species 0.000 description 1
- 206010024380 Leukoderma Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- ONIBWKKTOPOVIA-SCSAIBSYSA-N OC([C@@H]1NCCC1)=O Chemical compound OC([C@@H]1NCCC1)=O ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 description 1
- PMMYEEVYMWASQN-QWWZWVQMSA-N O[C@H](C1)CN[C@H]1C(O)=O Chemical compound O[C@H](C1)CN[C@H]1C(O)=O PMMYEEVYMWASQN-QWWZWVQMSA-N 0.000 description 1
- 208000017678 Ota naevus Diseases 0.000 description 1
- 241000287127 Passeridae Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 208000009077 Pigmented Nevus Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 241000031670 Saccharopolyspora thermophila Species 0.000 description 1
- 235000002953 Saxifraga stolonifera Nutrition 0.000 description 1
- 244000288377 Saxifraga stolonifera Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 244000040738 Sesamum orientale Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 102100027340 Slit homolog 2 protein Human genes 0.000 description 1
- 101710133576 Slit homolog 2 protein Proteins 0.000 description 1
- 229920002197 Sodium polyaspartate Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- XKMYWNHZAQUEPY-YZGJEOKZSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] 12-hydroxyoctadecanoate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCC(O)CCCCCC)C1 XKMYWNHZAQUEPY-YZGJEOKZSA-N 0.000 description 1
- ZVQOOHYFBIDMTQ-UHFFFAOYSA-N [methyl(oxido){1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-lambda(6)-sulfanylidene]cyanamide Chemical compound N#CN=S(C)(=O)C(C)C1=CC=C(C(F)(F)F)N=C1 ZVQOOHYFBIDMTQ-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960003589 arginine hydrochloride Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- XNEFYCZVKIDDMS-UHFFFAOYSA-N avobenzone Chemical compound C1=CC(OC)=CC=C1C(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 XNEFYCZVKIDDMS-UHFFFAOYSA-N 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 239000003788 bath preparation Substances 0.000 description 1
- IWWCATWBROCMCW-UHFFFAOYSA-N batyl alcohol Natural products CCCCCCCCCCCCCCCCCCOC(O)CO IWWCATWBROCMCW-UHFFFAOYSA-N 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 150000003939 benzylamines Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 208000007047 blue nevus Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000021329 brown rice Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229940072104 cholesteryl hydroxystearate Drugs 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- LFSBSHDDAGNCTM-UHFFFAOYSA-N cobalt(2+);oxygen(2-);titanium(4+) Chemical compound [O-2].[O-2].[O-2].[Ti+4].[Co+2] LFSBSHDDAGNCTM-UHFFFAOYSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- HRUVKSKSDDVGMC-JDYVBSGKSA-L disodium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;sulfate Chemical compound [Na+].[Na+].OS([O-])(=O)=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] HRUVKSKSDDVGMC-JDYVBSGKSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 229940072117 fennel extract Drugs 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 229940074052 glyceryl isostearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- KWLMIXQRALPRBC-UHFFFAOYSA-L hectorite Chemical compound [Li+].[OH-].[OH-].[Na+].[Mg+2].O1[Si]2([O-])O[Si]1([O-])O[Si]([O-])(O1)O[Si]1([O-])O2 KWLMIXQRALPRBC-UHFFFAOYSA-L 0.000 description 1
- 229910000271 hectorite Inorganic materials 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- DWMMZQMXUWUJME-UHFFFAOYSA-N hexadecyl octanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCC DWMMZQMXUWUJME-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940072106 hydroxystearate Drugs 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 description 1
- 235000012902 lepidium meyenii Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- HOVAGTYPODGVJG-UHFFFAOYSA-N methyl beta-galactoside Natural products COC1OC(CO)C(O)C(O)C1O HOVAGTYPODGVJG-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 208000004942 nevus of Ota Diseases 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- WNIFXKPDILJURQ-JKPOUOEOSA-N octadecyl (2s,4as,6ar,6as,6br,8ar,10s,12as,14br)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1h-picene-2-carboxylate Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@](C(=O)OCCCCCCCCCCCCCCCCCC)(C)C[C@H]5C4=CC(=O)[C@@H]3[C@]21C WNIFXKPDILJURQ-JKPOUOEOSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229940069265 ophthalmic ointment Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940113116 polyethylene glycol 1000 Drugs 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920001290 polyvinyl ester Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 239000010668 rosemary oil Substances 0.000 description 1
- 229940058206 rosemary oil Drugs 0.000 description 1
- 239000010670 sage oil Substances 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 235000003687 soy isoflavones Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- SHWIJIJNPFXOFS-UHFFFAOYSA-N thiotaurine Chemical compound NCCS(O)(=O)=S SHWIJIJNPFXOFS-UHFFFAOYSA-N 0.000 description 1
- RUJLHPZAKCVICY-UHFFFAOYSA-J thorium(4+);disulfate Chemical compound [Th+4].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O RUJLHPZAKCVICY-UHFFFAOYSA-J 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- QPQANCNBWQXGTQ-UHFFFAOYSA-N trihydroxy(trimethylsilylperoxy)silane Chemical compound C[Si](C)(C)OO[Si](O)(O)O QPQANCNBWQXGTQ-UHFFFAOYSA-N 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0212—Face masks
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0216—Solid or semisolid forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/92—Oral administration
Definitions
- the present invention relates to a whitening agent and a cosmetic method for whitening the skin, and specifically, one or two kinds selected from the group consisting of 4-cis-hydroxyproline and derivatives and / or salts thereof.
- the present invention relates to a whitening agent comprising the above compound and a cosmetic method for whitening the skin including the step of administering the whitening agent.
- Melanin which is a skin pigment, is produced by melanocytes existing in the vicinity of the basement membrane of the epidermis, moves to the skin surface together with the epidermal cells in the form of being embraced by the epidermal cells, and finally peels off from the skin as plaque.
- Pigmental abnormalities such as skin darkening, spots, and buckwheat are caused by abnormal increase and deposition of melanin in the epidermis, and involvement of ultraviolet rays, female hormones, genetic factors, etc. has been pointed out. Therefore, whitening agents that reduce the deposition of skin pigments by suppressing melanin production have been developed (Patent Documents 1 and 2, Non-Patent Documents 1 and 2).
- the reducing agent hydroquinone has a whitening effect and is designated as a quasi-drug as a preventive agent for pigment spot formation by ultraviolet rays.
- a compound having an inhibitory activity against tyrosinase, an enzyme that catalyzes the first two-stage reaction of melanin synthesis, is considered useful as a whitening agent. So far, compounds such as methyl gentisate, benzimidazole, and resorcinol have been developed as whitening agents (Patent Documents 1 and 2).
- Non-patent Document 1 hydroquinone is known to have side effects such as skin irritation and mutagenic activity in Chinese hamster V79 cells.
- methyl gentisate has no such mutagenic activity
- methyl gentisate has a molecular weight of 168, and it is necessary to develop a whitening agent with a lower molecular weight, fewer synthesis steps, and lower manufacturing costs. is there.
- the present invention provides a whitening agent containing one or more compounds selected from the group consisting of 4-cis-hydroxyproline and derivatives and / or salts thereof.
- the 4-cis-hydroxyproline may be 4-cis-L-hydroxyproline and / or 4-cis-D-hydroxyproline.
- the present invention provides a cosmetic composition containing the whitening agent of the present invention.
- the cosmetic composition of the present invention may be a skin external preparation.
- the present invention provides a food composition containing the whitening agent of the present invention.
- the present invention provides a pharmaceutical composition containing the whitening agent of the present invention.
- the pharmaceutical composition of the present invention may be a skin external preparation.
- the present invention provides a cosmetic method for whitening the skin, comprising the step of administering one or more compounds selected from the group consisting of 4-cis-hydroxyproline and derivatives and / or salts thereof. To do.
- the 4-cis-hydroxyproline may be 4-cis-L-hydroxyproline and / or 4-cis-D-hydroxyproline.
- the step of administering the compound may be applied externally to the skin surface.
- the step of administering the compound may be orally applied.
- the present invention relates to a pharmaceutical composition for treating a disease associated with abnormal skin pigmentation, comprising one or more compounds selected from the group consisting of 4-cis-hydroxyproline and derivatives and / or salts thereof.
- a pharmaceutical composition for treating a disease associated with abnormal skin pigmentation comprising one or more compounds selected from the group consisting of 4-cis-hydroxyproline and derivatives and / or salts thereof.
- the 4-cis-hydroxyproline may be 4-cis-L-hydroxyproline and / or 4-cis-D-hydroxyproline.
- hydroxyproline In hydroxyproline, whether the hydroxyl position is the 3rd or 4th position (positional isomer), the stereoisomer is a cis or trans form (geometric isomer), or the proline is a D or L form (optical isomer). There are 8 types of stereoisomers. Hydroxyproline generally exists in nature as 4-trans-L-hydroxyproline, but the presence of other stereoisomers is known to be very limited. The structural formulas of geometrical isomers and optical isomers of 4-hydroxyproline are shown below.
- hydroxyproline refers to all compounds in which the 3-position or 4-position of the heterocyclic ring of proline L- or D-form is hydroxylated.
- the 4-hydroxylated compounds include 4-cis-L-hydroxyproline, 4-cis-D-hydroxyproline, 4-trans-L-hydroxyproline and 4-trans-D-hydroxyproline. It is.
- 4-cis-hydroxyproline means 4-cis-L-hydroxyproline alone, 4-cis-D-hydroxyproline alone, 4-cis-L-hydroxyproline and 4-cis-D. -Any of hydroxyproline.
- whitening or “whitening the skin” means disappearance, reduction, and / or prevention of skin darkening, pigment abnormalities such as spots and freckles.
- the mechanism of whitening is the suppression of melanocyte differentiation, inhibition of melanin production in melanocytes by inhibition of melanin-producing enzymes such as tyrosinase, decomposition, reduction, decolorization, etc. of produced melanin, Including but not limited to excretion promotion.
- “disease associated with skin pigmentation” means sparrow egg spot, liver spot, pigmented nevus, blue nevus, Ota nevus, acquired dermal melanocytosis, reticulolimbic pigmentation , Progressive limb scleroderma, senile pigmented spot, pigmented contact dermatitis, sunburn, photovalvular pigmented spot, phototrophic leukoderma, chemical / drug-induced pigmentation, Addison's disease, pigmentation due to pregnancy Including but not limited to deposition, Crow / Fukase syndrome, etc.
- a derivative of 4-cis-hydroxyproline is any atom other than hydrogen constituting 4-cis-hydroxyproline, provided that the whitening effect of 4-cis-hydroxyproline is not impaired.
- Any of the above atomic groups includes a protecting group such as an N-phenylacetyl group, 4,4′-dimethyloxytrityl (DMT) group, and a biopolymer such as a protein, peptide, sugar, lipid, nucleic acid, etc.
- synthetic polymers such as polystyrene, polyethylene, polyvinyl, and polyester, and functional groups such as ester groups, but are not limited thereto.
- the ester group may include, for example, methyl ester, ethyl ester, other aliphatic esters, or aromatic esters.
- the salt of 4-cis-hydroxyproline means any salt including a metal salt, an amine salt and the like, provided that the whitening effect of 4-cis-hydroxyproline is not impaired.
- the metal salt may include an alkali metal salt, an alkaline earth metal salt, and the like.
- the amine salt may include a triethylamine salt, a benzylamine salt, or the like.
- 4-cis-hydroxyproline of the present invention alone reduces melanin in a concentration range of 33.3 to 333 ppm or 11.1 to 33.3 ppm with respect to cultured mouse B16 melanoma cells. Has an effect. Therefore, the amount of 4-cis-hydroxyproline contained in the pharmaceutical composition, cosmetic composition and food composition of the present invention is such that 4-cis-hydroxyproline alone in this concentration range is converted into melanocytes in living skin tissue. Any content is acceptable provided it is delivered. When the composition of the present invention is an external preparation, the content of 4-cis-hydroxyproline ranges from 0.000015% to 50% by weight or the maximum weight concentration that can be blended in the total amount of the composition of the present invention. I just need it.
- the content of 4-cis-hydroxyproline is preferably 0.00003 wt% to 30 wt%, and most preferably 0.0003 wt% to 3 wt%.
- the content of 4-cis-hydroxyproline may be in the range of 0.00001 wt% to 100 wt%.
- the content of 4-cis-hydroxyproline is desirably 0.00002 wt% to 80 wt%, and most desirably 0.0002 wt% to 60 wt%.
- the lower limit of the daily intake of 4-cis-hydroxyproline may be 0.01 ng, 0.1 ng or 1 ng per kg body weight.
- the cosmetic composition of the present invention requires other components used in skin external preparations such as cosmetics and pharmaceuticals including quasi drugs, provided that the whitening effect of 4-cis-hydroxyproline is not impaired. It can mix
- the other components include oils, surfactants, powders, coloring materials, water, alcohols, thickeners, chelating agents, silicones, antioxidants, ultraviolet absorbers, and humectants. , Fragrances, various medicinal ingredients, preservatives, pH adjusters, neutralizers and the like.
- the cosmetic composition of the present invention may be any ophthalmic ointment, cream, milky lotion, lotion, pack, bath preparation, etc., as long as it is used for conventional skin external preparations and cosmetic compositions, and the dosage form is not particularly limited.
- the food composition of the present invention includes 4-cis-hydroxyproline alone, a salt of 4-cis-hydroxyproline and / or a derivative capable of releasing 4-cis-hydroxyproline by a drug metabolizing enzyme or the like in vivo. -Containing seasonings, coloring agents, preservatives and other food-acceptable ingredients, provided that the whitening effect of cis-hydroxyproline is not impaired.
- the food composition of the present invention may be any conventional food composition such as soft drinks, gummi, candy, and tablet confectionery, and is not limited to such examples.
- the pharmaceutical composition of the present invention includes 4-cis-hydroxyproline alone, a salt of 4-cis-hydroxyproline and / or a derivative capable of releasing 4-cis-hydroxyproline by a drug metabolizing enzyme or the like in vivo. -On condition that the whitening effect of cis-hydroxyproline is not impaired, it may further contain one or more kinds of ingredients and / or pharmaceutically acceptable additives effective for the treatment of other diseases.
- the additives include diluents and swelling agents, binders and adhesives, lubricants, glidants, plasticizers, disintegrants, carrier solvents, buffering agents, colorants, fragrances, Includes, but is not limited to, sweeteners, preservatives and stabilizers, adsorbents, and other pharmaceutical additives known to those skilled in the art.
- 4 is a graph showing the effect of 4-trans-L-hydroxyproline on cell proliferation and melanin reduction.
- 4 is a graph showing the effect of 4-trans-L-hydroxyproline on cell proliferation and melanin reduction.
- Cell culture Mouse B16 melanoma cells were used as cells.
- the cells were seeded in a 6-well plate at 1 ⁇ 10 5 cells / well, and cultured using a commercially available medium (Eagle MEM, Nissui Pharmaceutical) supplemented with 10% fetal calf serum.
- the cells were cultured at 37 ° C., 5% CO 2 and saturated water vapor atmosphere.
- 4-cis-L-hydroxyproline, 4-cis-D-hydroxyproline and 4-trans-L-hydroxyproline were purchased from Sigma Aldrich Japan Co., Ltd.
- 4-trans-D-hydroxyproline was purchased from Bachem.
- hydroxyproline When examining the effects of hydroxyproline on cell proliferation and melanin reduction, 4-trans-L-hydroxyproline, 4-trans-D-hydroxyproline, 4-cis after cell culture for 24 hours. Concentrated aqueous solutions of various concentrations of -L-hydroxyproline and 4-cis-D-hydroxyproline were prepared, and after adding the same volume, they were cultured for 3 days and used for the experiment. In the control experiment, the volume of water was added.
- FIG. 1A shows the number of cells when the control of mouse B16 melanoma cells added with -D-hydroxyproline was taken as 100%.
- FIG. 1A shows the number of cells when the control after addition of 4-trans-L-hydroxyproline at various concentrations is taken as 100%, 95% at 3.33 ppm, 103% at 11.1 ppm, 33. It was 99% at 3 ppm, 101% at 333 ppm, and 94% at 2690 ppm.
- FIG. 1A shows the concentrations of 4-trans-L-hydroxyproline, 4-trans-D-hydroxyproline, 4-cis-L-hydroxyproline and 4-cis The experimental results of examining the number of cells when the control of mouse B16 melanoma cells added with -D-hydroxyproline was taken as 100% are shown.
- FIG. 1A shows the number of cells when the control after addition of 4-trans-L-hydroxyproline at various concentrations is taken as 100%, 95% at 3.33 ppm, 103% at 11.1 ppm, 33.
- FIG. 1B shows the number of cells when the control after addition of 4-trans-D-hydroxyproline at various concentrations was taken as 100%, 3.3% at 98%, 11.1 ppm at 100%, 33. It was 101% at 3 ppm, 105% at 333 ppm, and 109% at 2690 ppm.
- FIG. 1C shows the number of cells at 100% control after addition of 4-cis-L-hydroxyproline at various concentrations, 93% at 3.33 ppm, 92% at 11.1 ppm, 33. It was 84% at 3 ppm.
- FIG. 1D shows the number of cells at 100% control after addition of 4-cis-D-hydroxyproline at various concentrations, 97% at 3.33 ppm, 98% at 11.1 ppm, 33.
- FIG. 1A shows the melanin percentage after adding 4-trans-L-hydroxyproline at various concentrations, 103% at 3.33 ppm, 108% at 11.1 ppm, 105% at 33.3 ppm, at 333 ppm. 104% and 107% at 2690 ppm.
- FIG. 1A shows the melanin percentage after adding 4-trans-L-hydroxyproline at various concentrations, 103% at 3.33 ppm, 108% at 11.1 ppm, 105% at 33.3 ppm, at 333 ppm. 104% and 107% at 2690 ppm.
- FIG. 1B shows the melanin content after adding 4-trans-D-hydroxyproline at various concentrations, 97% at 3.33 ppm, 99% at 11.1 ppm, 99% at 33.3 ppm, at 333 ppm. It was 110% at 101% and 2690 ppm.
- FIG. 1C shows the melanin content after adding 4-cis-L-hydroxyproline at various concentrations, 92% at 3.33 ppm, 83% at 11.1 ppm and 30% at 33.3 ppm.
- FIG. 1D shows the melanin content after addition of 4-cis-D-hydroxyproline at various concentrations, 100% at 3.33 ppm, 98% at 11.1 ppm, 96% at 33.3 ppm and 333 ppm. It was 32%.
- FIG. 2A shows the number of cells when the control after adding 4-trans-L-hydroxyproline at various concentrations is taken as 100%, 33.3 ppm at 95%, 50 ppm at 100%, 100 ppm at 98%. And 102% at 333 ppm.
- FIG. 2A shows the number of cells when the control after adding 4-trans-L-hydroxyproline at various concentrations is taken as 100%, 33.3 ppm at 95%, 50 ppm at 100%, 100 ppm at 98%. And 102% at 333 ppm.
- FIG. 2B shows the number of cells at 100% control after addition of 4-cis-D-hydroxyproline at various concentrations, 97% at 33.3 ppm, 93% at 50 ppm, 95% at 100 ppm. And 89% at 333 ppm.
- FIG. 2C shows the number of cells when the control after addition of a mixture of both at various concentrations is taken as 100%, 97% at 66.6 ppm, 100% at 100 ppm, 98% at 200 ppm and 100% at 666 ppm. %Met. From the above results, the number of cells when the control was 100% was not observed when the concentration of the mixture of 4-trans-L-hydroxyproline and 4-cis-D-hydroxyproline was 66.6 ppm to 666 ppm. It was revealed that the cell proliferation of B16 melanoma cells was not affected.
- FIGS. 2A-C black bars
- mouth B16 melanoma cell is shown.
- the error bar for each experimental condition indicates the standard deviation of the measured value of the experimental result repeated twice under the same condition.
- FIG. 2A shows the melanin content after adding 4-trans-L-hydroxyproline at various concentrations: 103% at 33.3 ppm, 104% at 50 ppm, 108% at 100 ppm and 112% at 333 ppm. It was.
- FIG. 1A shows the melanin content after adding 4-trans-L-hydroxyproline at various concentrations: 103% at 33.3 ppm, 104% at 50 ppm, 108% at 100 ppm and 112% at 333 ppm. It was.
- FIG. 2B shows the melanin content after adding 4-cis-D-hydroxyproline at various concentrations: 90% at 33.3 ppm, 85% at 50 ppm, 72% at 100 ppm and 32% at 333 ppm. It was.
- FIG. 2C shows the amount of melanin after adding the mixture at various concentrations: 97% at 66.6 ppm, 93% at 100 ppm, 86% at 200 ppm and 57% at 666 ppm. From the above results, it was shown that 4-cis-D-hydroxyproline significantly suppresses melanin synthesis from 33.3 ppm in a concentration-dependent manner. However, in the case where the mixture of both was added, the amount of 4-cis-D-hydroxyproline added alone was equivalent to the amount added alone, but no significant suppression of the melanin amount was shown.
- FIG. 3 shows 4-trans-L-hydroxyproline, 4-cis-D-hydroxyproline, and the mixture solution at various concentrations.
- mouth B16 melanoma cell which added No. is shown.
- the error bar for each experimental condition indicates the standard deviation of the measured value of the experimental result repeated twice under the same condition.
- FIG. 3A shows the number of cells with 100% control after addition of 4-trans-L-hydroxyproline at various concentrations, 100% at 333 ppm, 96% at 480 ppm, 102% at 666 ppm, and 1332 ppm. 99%.
- FIG. 3A shows the number of cells with 100% control after addition of 4-trans-L-hydroxyproline at various concentrations, 100% at 333 ppm, 96% at 480 ppm, 102% at 666 ppm, and 1332 ppm. 99%.
- FIG. 3B shows the number of cells at 100% control after addition of 4-cis-D-hydroxyproline at various concentrations, 93% at 33.3 ppm, 92% at 50 ppm, 91% at 100 ppm. And 88% at 333 ppm.
- FIG. 3C shows a mixture of 4-trans-L-hydroxyproline and 4-cis-D-hydroxyproline at different concentrations after addition of different mixing ratios (4-cis-D: 4-trans-L). The number of cells when the control is 100% is shown.
- FIG. 3 shows 4-trans-L-hydroxyproline, 4-cis-D-hydroxyproline, and the liquid mixture at various concentrations.
- mouth B16 melanoma cell is shown.
- the error bar for each experimental condition indicates the standard deviation of the measured value of the experimental result repeated twice under the same condition.
- FIG. 3A shows the melanin content after adding 4-trans-L-hydroxyproline at various concentrations, 103% at 333 ppm, 99% at 480 ppm, 107% at 666 ppm and 102% at 1332 ppm.
- FIG. 3A shows the melanin content after adding 4-trans-L-hydroxyproline at various concentrations, 103% at 333 ppm, 99% at 480 ppm, 107% at 666 ppm and 102% at 1332 ppm.
- FIG. 3B shows the melanin content after adding 4-cis-D-hydroxyproline at various concentrations: 92% at 33.3 ppm, 84% at 50 ppm, 75% at 100 ppm and 37% at 333 ppm. It was.
- FIG. 3C shows a mixture of 4-trans-L-hydroxyproline and 4-cis-D-hydroxyproline at different concentrations after addition of different mixing ratios (4-cis-D: 4-trans-L).
- the melanin content rate was 62% at 333 ppm: 333 pm, 66% at 333 ppm: 480 ppm, 72% at 333 ppm: 666 ppm, and 69% at 333 ppm: 1332 ppm.
- Formulation Example 1 (Emulsion formulation) (Composition) Compounding amount (% by weight) 4-cis-hydroxyproline 0.42 Behenyl alcohol 0.2 Cetanol 0.5 Glycerin mono fatty acid ester 1.8 Hardened castor oil POE (60) 1.0 White petrolatum 2.0 Liquid paraffin 10.0 Isopropyl myristate 3.0 Methyl polysiloxane (6cs) 1.5 Concentrated glycerin 13.0 Dipropylene glycol 2.0 Carboxyvinyl polymer 0.25 Sodium hyaluronate 0.005 Potassium hydroxide Appropriate amount of lactic acid Appropriate amount of sodium edetate Appropriate amount of ethyl paraben Appropriate amount of purified water Residue 100.000
- Formulation Example 2 (Patch) (Composition) Compounding amount (% by weight) 4-cis-hydroxyproline 0.3 Polyacrylic acid 3.0 Sodium polyacrylate 2.5 Gelatin 0.5 Sodium carboxymethylcellulose 4.0 Polyvinyl alcohol 0.3 Concentrated glycerin 14.0 1,3-butylene glycol 12.0 Aluminum hydroxide 0.1 Sodium edetate 0.03 Methylparaben 0.1 Purified water residue 100.00
- Formulation Example 3 (tablet) (Composition) Formulation amount (mg / tablet) 4-cis-hydroxyproline 360.5 Lactose 102.4 Carboxymethylcellulose calcium 29.9 Hydroxypropylcellulose 6.8 Magnesium stearate 5.2 Crystalline cellulose 10.2 515.0
- Formulation Example 4 (tablet) (Composition) Formulation amount (mg / tablet) Sucrose ester 70 Crystalline cellulose 74 Methylcellulose 36 Glycerin 25 4-cis-hydroxyproline 475 N-acetylglucosamine 200 Hyaluronic acid 150 Vitamin E 30 Vitamin B6 20 Vitamin B2 10 ⁇ -Lipoic acid 20 Coenzyme Q10 40 Ceramide (konjac extract) 50 L-proline 300 1500
- Formulation Example 5 (soft capsule) (Composition) Blending amount (mg / 1 capsule) Edible soybean oil 530 Eucommia extract 50 Carrot extract 50 4-cis-hydroxyproline 100 Royal Jelly 50 Maca 30 GABA 30 Beeslow 60 Gelatin 375 Glycerin 120 Glycerin fatty acid ester 105 1500
- Formulation Example 6 soft capsule (Composition) Blending amount (mg / 1 capsule) Brown rice germ oil 659 4-cis-hydroxyproline 500 Resveratrol 1 Lotus germ extract 100 Elastin 180 DNA 30 Folic acid 30 1500
- Formulation Example 7 (granule) (Composition) Blending amount (mg / pack) 4-cis-hydroxyproline 400 Vitamin C 100 Soy isoflavone 250 Reduced lactose 300 Soybean oligosaccharide 36 Erythritol 36 Dextrin 30 Fragrance 24 Citric acid 24 1200
- Formulation Example 8 (Drink) (Composition) Compounding amount (in g / 60 mL) Eucommia extract 1.6 Carrot extract 1.6 4-cis-hydroxyproline 1.6 Reduced maltose starch syrup 28 Erythritol 8 Citric acid 2 Fragrance 1.3 N-acetylglucosamine 1 Hyaluronic acid Na 0.5 Vitamin E 0.3 Vitamin B6 0.2 Vitamin B2 0.1 ⁇ -Lipoic acid 0.2 Coenzyme Q10 1.2 Ceramide (konjac extract) 0.4 L-proline 2 Purified water residue 60
- Formulation Example 12 (French dressing) (Composition) Blending amount (g) Salad oil 27.0 Vinegar 30.0 Sodium chloride 0.9 4-cis-hydroxyproline 1.1 Pepper 1.0 60.0
- Formulation Example 13 (mayonnaise) (Composition) Blending amount (g) Salad oil 134.0 Vinegar 5 Sodium chloride 0.9 4-cis-hydroxyproline 1 Yolk 18 Sugar 0.2 Pepper 0.9 160.0
- Formulation Example 14 (French bread) (Composition) Blending amount (g) Powerful powder 140 Soft flour 60 Sodium chloride 3 Sugar 6 4-cis-hydroxyproline 2 Dry yeast 4 Lukewarm water 128 343
- Production method of Formulation Example 14 (French bread) Pre-fermented with 1 g of sugar and dry yeast in lukewarm water. Put 5 grams of flour, soft flour, sodium chloride and sugar and 4-cis-hydroxyproline in a bowl and pre-fermented yeast. After kneading sufficiently, it is made into a sphere and subjected to primary fermentation at 30 ° C. The dough is kneaded again, rested, shaped into a suitable shape, and finally fermented using an electronic fermenter. Bake in a 220 ° C oven for 30 minutes.
- Formulation Example 16 (yogurt) (Composition) Blending amount (g) Milk 880 L. Bulgaricus 50 S. Thermophilus 50 4-cis-hydroxyproline 20 1000
- Formulation Example 17 (sprinkle) (Composition) Blending amount (g) 4-cis-hydroxyproline 50 Paste 15 L-glutamic acid Na 10 Sodium chloride 2 Roasted sesame 10 Crusher Clause 10 Sugar 1 Soy sauce 2 100
- Formulation Example 18 (Seasoning and natto sauce) (Composition) Blending amount (g) Commercial natto sauce 9.9 4-cis-hydroxyproline 0.1 10
- natto may be made using a bacterium that produces a large amount of 4-cis-D-hydroxyproline.
- Production method 20 (Moromi black vinegar) Instead of adding 4-cis-hydroxyproline or its salt, make vinegar, black vinegar and moromi using bacteria that produce a lot of 4-cis-hydroxyproline. Also good.
- Formulation Example 21 (cream) (Composition) Compounding amount (%) Liquid paraffin 3 Vaseline 1 Dimethylpolysiloxane 1 Stearyl alcohol 1.8 Behenyl alcohol 1.6 Glycerin 8 Dipropylene glycol 5 Macadamia nut oil 2 Hardened oil 3 Squalane 6 Stearic acid 2 Cholesteryl hydroxystearate 0.5 Cetyl 2-ethylhexanoate 4 Polyoxyethylene hydrogenated castor oil 0.5 Self-emulsifying glyceryl monostearate 3 Potassium hydroxide 0.15 Sodium hexametaphosphate 0.05 Trimethylglycine 2 ⁇ -tocopherol 2-L-ascorbic acid potassium phosphate diester 1 Tocopherol acetate 0.1 4-cis-hydroxyproline 4 Paraben appropriate amount edetate trisodium 0.05 4-t-butyl-4′-methoxydibenzoylmethane 0.05 Diparamethoxycinnamic acid mono-2-eth
- Formulation Example 22 (Body Cream) (Composition) Compounding amount (%) Dimethylpolysiloxane 3 Decamethylcyclopentasiloxane 13 Dodecamethylcyclohexasiloxane 12 Polyoxyethylene methylpolysiloxane copolymer 1 Ethanol 2 Isopropanol 1 Glycerin 3 Dipropylene glycol 5 Polyethylene glycol 6000 5 Sodium hexametaphosphate 0.05 Tocopherol acetate 0.1 4-cis-hydroxyproline 5 Fennel extract 0.1 Hamelis extract 0.1 Carrot extract 0.1 L-menthol proper amount paraoxybenzoate proper amount edetate trisodium 0.05 Dimorpholinopyridazinone 0.01 Methyl bis (trimethylsiloxy) trimethoxycinnamate Silyl isopentyl 0.1 Yellow iron oxide Appropriate amount Cobalt titanate Appropriate amount Dimethyl distearyl ammonium hectorite 1.5 Polyvinyl
- Formulation Example 23 (gel agent) (Composition) Compounding amount (%) Dimethylpolysiloxane 5 Glycerin 2 1,3-butylene glycol 5 Polyethylene glycol 1500 3 Polyethylene glycol 20000 3 Cetyl octanoate 3 Citric acid 0.01 Sodium citrate 0.1 Sodium hexametaphosphate 0.1 Dipotassium glycyrrhizinate 0.1 4-cis-hydroxyproline 2 Tocopherol acetate 0.1 Ogon Extract 0.1 Yukinoshita extract 0.1 Edetate trisodium 0.1 Xanthan gum 0.3 Acrylic acid / alkyl methacrylate copolymer (Pemulene TR-2) 0.05 Agar powder 1.5 Phenoxyethanol Appropriate amount Dibutylhydroxytoluene Appropriate amount of purified water Residue 100.00
- Formulation Example 24 (Peel-off mask) (Composition) Compounding amount (%) Ethanol 10 1,3-butylene glycol 6 Polyethylene glycol 4000 2 Olive oil 1 Macadamia nut oil 1 Phytosteryl hydroxystearate 0.05 Lactic acid 0.05 Sodium lactate 0.1 L-ascorbic acid sulfate disodium salt 0.1 ⁇ -tocopherol 2-L-ascorbic acid potassium phosphate diester 0.1 4-cis-hydroxyproline 10 Fish collagen 0.1 Chondroitin thorium sulfate 0.1 Sodium carboxymethylcellulose 0.2 Polyvinyl alcohol 12 Paraoxybenzoic acid ester Appropriate amount of fragrance Appropriate amount of purified water Residue 100.00
- Formulation Example 25 Composition (impregnation mask) (Composition) Compounding amount (%) Glycerin 1 1,3-butylene glycol 8 Xylit 2 Polyethylene glycol 1500 2 Rosemary oil 0.01 Sage oil 0.1 Citric acid 0.02 Sodium citrate 0.08 Sodium hexametaphosphate 0.01 Hydroxypropyl- ⁇ -cyclodextrin 0.1 4-cis-hydroxyproline 0.5 Birch extract 0.1 Lavender oil 0.01 Xanthan gum 0.05 Carboxyvinyl polymer 0.15 P-Hydroxybenzoate appropriate amount purified water remaining 100.00
- Formulation Example 26 (Emulsion) (Composition) Compounding amount (%) Liquid paraffin 7 Vaseline 3 Decamethylcyclopentasiloxane 2 Behenyl alcohol 1.5 Glycerin 5 Dipropylene glycol 7 Polyethylene glycol 1500 2 Jojoba oil 1 Isostearic acid 0.5 Stearic acid 0.5 Behenic acid 0.5 Tetra-2-ethylhexanoic acid pentaerythrit 3 Cetyl 2-ethylhexanoate 3 Glycerol monostearate 1 Polyoxyethylene glyceryl monostearate 1 Potassium hydroxide 0.1 Sodium hexametaphosphate 0.05 Stearyl glycyrrhetinate 0.05 4-cis-hydroxyproline 1 Royal Jelly Extract 0.1 Yeast extract 0.1 Tocopherol acetate 0.1 Acetylated sodium hyaluronate 0.1 Edetate trisodium 0.05 4-tert-butyl-4′-methoxydibenz
- Formulation Example 27 (milky lotion) (Composition) Compounding amount (%) Dimethylpolysiloxane 2 Behenyl alcohol 1 Batyl alcohol 0.5 Glycerin 5 1,3-butylene glycol 7 Erythritol 2 Hardened oil 3 Squalane 6 Tetra-2-ethylhexanoic acid pentaerythrit slit 2 Polyoxyethylene glyceryl isostearate 1 Polyoxyethylene glyceryl monostearate 1 4-cis-hydroxyproline 0.3 Potassium hydroxide appropriate amount Sodium hexametaphosphate 0.05 Phenoxyethanol appropriate amount carboxyvinyl polymer 0.1 Purified water residue 100.00
- Formulation Example 28 (lotion) (Composition) Compounding amount (%) Ethyl alcohol 5 Glycerin 1 1,3-butylene glycol 5 Polyoxyethylene polyoxypropylene decyl tetradecyl ether 0.2 Sodium hexametaphosphate 0.03 Trimethylglycine 1 Sodium polyaspartate 0.1 ⁇ -tocopherol 2-L-ascorbic acid potassium phosphate diester 0.1 Thiotaurine 0.1 4-cis-hydroxyproline 8 EDTA3 sodium 0.1 Carboxyvinyl polymer 0.05 Potassium hydroxide 0.02 Phenoxyethanol appropriate amount perfume appropriate amount purified water remaining 100.00
- Formulation Example 29 (lotion) (Composition) Compounding amount (%) Ethanol 10 Dipropylene glycol 1 Polyethylene glycol 1000 1 Polyoxyethylene methyl glucoside 1 Jojoba oil 0.01 Glyceryl tri-2-ethylhexanoate 0.1 Polyoxyethylene hydrogenated castor oil 0.2 Polyglyceryl diisostearate 0.15 N-stearoyl-L-glutamate sodium 0.1 Citric acid 0.05 Sodium citrate 0.2 Potassium hydroxide 0.4 Dipotassium glycyrrhizinate 0.1 Arginine hydrochloride 0.1 L-ascorbic acid 2-glucoside 2 4-cis-hydroxyproline 0.5 Edetate trisodium 0.05 2-Ethylhexyl paramethoxycinnamate 0.01 Dibutylhydroxytoluene Appropriate amount Paraben Appropriate amount Deep sea water 3 Perfume Appropriate amount of purified water 100.00
- Formulation Example 30 (Aerosol urea external preparation stock solution) (Composition) Compounding amount (% by weight) Ethanol 15.0 Polyoxyethylene hydrogenated castor oil 50 1.5 Diphenhydramine 1.0 Jibcaine 2.0 Tocopherol acetate 0.5 4-cis-hydroxyproline 0.1 Isostearic acid 0.1 1,3-butylene glycol 3.0 Polyethylene glycol 400 3.0 Camphor 0.05 Urea 20.0 Purified water residue 100.00
- Formulation Example 31 (Aerosol urea propellant) (Composition) Compounding amount (% by weight) Aerosol urea external preparation stock solution 65.0 Dimethyl ether 35.0 100.00
- Formulation Example 31 (Aerosol Urea Propellant) Filling Method
- An aerosol urea preparation is prepared by filling an inner surface Teflon (registered trademark) coated pressure-resistant aerosol aluminum can with an aerosol urea external preparation stock solution and dimethyl ether.
Abstract
Description
細胞はマウスB16メラノーマ細胞を用いた。前記細胞は1x105個/ウェルとなるように6ウェルプレートに播種され、10% ウシ胎児血清を添加した市販の培地(Eagle MEM、 日水製薬)を用いて培養された。前記細胞は、37°C、5%CO2及び飽和水蒸気雰囲気下で培養された。
本発明の実施例において用いられるヒドロキシプロリンのうち、4-シス-L-ヒドロキシプロリン、4-シス-D-ヒドロキシプロリン及び4-トランス-L-ヒドロキシプロリンはシグマ アルドリッチ ジャパン株式会社から購入され、4-トランス-D-ヒドロキシプロリンはBachem社から購入された。
ヒドロキシプロリンの細胞増殖及びメラニン量低減の効果を検討する場合には、上記24時間細胞培養後に、4-トランス-L-ヒドロキシプロリン、4-トランス-D-ヒドロキシプロリン、4-シス-L-ヒドロキシプロリン及び4-シス-D-ヒドロキシプロリンのさまざまな濃度の濃縮水溶液を用意して、同一体積を添加後に、3日間培養して実験に用いた。なお対照実験では前記体積の水が添加された。
試験物質溶液添加から3日後に培地を吸引除去した後、10%のalamarBlue(商標、Biosource、バイオソース・インターナショナル)溶液を含むEagle’s-MEM培地を添加して、37℃で反応させた。30分後に励起波長544nm、測定波長590nmで蛍光を測定し、その値を細胞数の相対値として、試験物質無添加群(溶媒のみ添加)に対する試験物質添加群の細胞数比率(%細胞数)を算出した。%細胞数が高いほど細胞毒性が低いことを意味し、80%未満のとき「毒性あり」と判断した。
図1A-D(ハッチング入りの棒)にさまざまな濃度で4-トランス-L-ヒドロキシプロリン、4-トランス-D-ヒドロキシプロリン、4-シス-L-ヒドロキシプロリン及び4-シス-D-ヒドロキシプロリンを添加したマウスB16メラノーマ細胞のコントロールを100%としたときの細胞数を調べた実験結果を示す。図1Aは、さまざまな濃度で4-トランス-L-ヒドロキシプロリンを添加した後のコントロールを100%としたときの細胞数を示し、3.33ppmで95%、11.1ppmで103%、33.3ppmで99%、333ppmで101%及び2690ppmで94%であった。図1Bは、さまざまな濃度で4-トランス-D-ヒドロキシプロリンを添加した後のコントロールを100%としたときの細胞数を示し、3.33ppmで98%、11.1ppmで100%、33.3ppmで101%、333ppmで105%及び2690ppmで109%であった。図1Cは、さまざまな濃度で4-シス-L-ヒドロキシプロリンを添加した後のコントロールを100%としたときの細胞数を示し、3.33ppmで93%、11.1ppmで92%、33.3ppmで84%であった。図1Dは、さまざまな濃度で4-シス-D-ヒドロキシプロリンを添加した後のコントロールを100%としたときの細胞数を示し、3.33ppmで97%、11.1ppmで98%、33.3ppmで101%及び333ppmで92%であった。以上の結果から、コントロールを100%としたときの細胞数は、4-トランス-L-ヒドロキシプロリン及び4-トランス-D-ヒドロキシプロリンでは2690ppmまで、4-シス-L-ヒドロキシプロリンでは33.3ppmまで、4-シス-D-ヒドロキシプロリンでは333ppmまでの濃度で認められず、マウスB16メラノーマ細胞の細胞生存に影響しないことが示された。
培地を吸引除去し、バッファー(リン酸緩衝液50mM、pH6.8)を用いて3回洗浄した後、1N NaOHを添加して細胞を溶解し、475nmの吸光度を測定した。この値をメラニン量の相対値として、試験物質無添加群(溶媒のみ添加)に対する試験物質添加群のメラニン量比率(%)を算出した。メラニン量比率が低いほどメラニン生成抑制効果が高いことを意味する。
前記測定法によって得られたメラニン量の測定値を用いて、4-トランス-L-ヒドロキシプロリン、4-トランス-D-ヒドロキシプロリン、4-シス-L-ヒドロキシプロリン及び4-シス-D-ヒドロキシプロリンを添加した細胞のメラニンの量を対照実験の細胞のメラニンの量で除算した百分率を算出してメラニン量率とした。
図1A-D(黒塗りの棒)にさまざまな濃度で4-トランス-L-ヒドロキシプロリン、4-トランス-D-ヒドロキシプロリン、4-シス-L-ヒドロキシプロリン及び4-シス-D-ヒドロキシプロリンを添加したマウスB16メラノーマ細胞のメラニン量低減の効果を調べた実験結果を示す。図1Aは、さまざまな濃度で4-トランス-L-ヒドロキシプロリンを添加した後のメラニン量率を示し、3.33ppmで103%、11.1ppmで108%、33.3ppmで105%、333ppmで104%及び2690ppmで107%であった。図1Bは、さまざまな濃度で4-トランス-D-ヒドロキシプロリンを添加した後のメラニン量率を示し、3.33ppmで97%、11.1ppmで99%、33.3ppmで99%、333ppmで101%及び2690ppmで110%であった。図1Cは、さまざまな濃度で4-シス-L-ヒドロキシプロリンを添加した後のメラニン量率を示し、3.33ppmで92%、11.1ppmで83%及び33.3ppmで30%であった。図1Dは、さまざまな濃度で4-シス-D-ヒドロキシプロリンを添加した後のメラニン量率を示し、3.33ppmで100%、11.1ppmで98%、33.3ppmで96%及び333ppmで32%であった。以上の結果から、4-トランス-L-ヒドロキシプロリン及び4-トランス-D-ヒドロキシプロリンにはメラニン量低減の効果がないことが示された。また、4-シス-L-ヒドロキシプロリン及び4-シス-D-ヒドロキシプロリンには濃度依存的にメラニン量低減の効果があることが示された。
4-トランス-L-ヒドロキシプロリン及び4-シス-D-ヒドロキシプロリンの混合液は、4-トランス-L-ヒドロキシプロリン及び4-シス-D-ヒドロキシプロリンが等量となるように調製されて実験に供された。細胞培養と、細胞数及びメラニンの定量及び評価とは前記実施例と同様に行なった。
図2A-C(ハッチング入りの棒)にさまざまな濃度で4-トランス-L-ヒドロキシプロリンと、4-シス-D-ヒドロキシプロリンと、両者の混合液とを添加したマウスB16メラノーマ細胞の細胞増殖を調べた実験結果を示す。各実験条件の誤差棒は同一条件で2回繰り返した実験結果の測定値の標準偏差を示す。図2Aは、さまざまな濃度で4-トランス-L-ヒドロキシプロリンを添加した後のコントロールを100%としたときの細胞数を示し、33.3ppmで95%、50ppmで100%、100ppmで98%及び333ppmで102%であった。図2Bは、さまざまな濃度で4-シス-D-ヒドロキシプロリンを添加した後のコントロールを100%としたときの細胞数を示し、33.3ppmで97%、50ppmで93%、100ppmで95%及び333ppmで89%であった。図2Cは、さまざまな濃度で両者の混合液を添加した後のコントロールを100%としたときの細胞数を示し、66.6ppmで97%、100ppmで100%、200ppmで98%及び666ppmで100%であった。以上の結果から、コントロールを100%としたときの細胞数は4-トランス-L-ヒドロキシプロリン及び4-シス-D-ヒドロキシプロリンの混合液の濃度が66.6ppmないし666ppmでは認められず、マウスB16メラノーマ細胞の細胞増殖に影響を与えないことが明らかとなった。
図2A-C(黒塗りの棒)にさまざまな濃度で4-トランス-L-ヒドロキシプロリンと、4-シス-D-ヒドロキシプロリンと、両者の混合液とを添加したマウスB16メラノーマ細胞のメラニン量の低減の効果を調べた実験結果を示す。各実験条件の誤差棒は同一条件で2回繰り返した実験結果の測定値の標準偏差を示す。図2Aは、さまざまな濃度で4-トランス-L-ヒドロキシプロリンを添加した後のメラニン量率を示し、33.3ppmで103%、50ppmで104%、100ppmで108%及び333ppmで112%であった。図2Bは、さまざまな濃度で4-シス-D-ヒドロキシプロリンを添加した後のメラニン量率を示し、33.3ppmで90%、50ppmで85%、100ppmで72%及び333ppmで32%であった。図2Cは、さまざまな濃度で前記混合液を添加した後のメラニン量率を示し、66.6ppmで97%、100ppmで93%、200ppmで86%及び666ppmで57%であった。以上の結果から、4-シス-D-ヒドロキシプロリンは33.3ppmから濃度依存的に顕著にメラニン合成を抑制することが示された。しかし、両者の混合液を添加したものでは、4-シス-D-ヒドロキシプロリンを単独で添加した量と等量が添加されているにもかかわらず、顕著なメラニン量の抑制を示さなかった。
4-トランス-L-ヒドロキシプロリン及び4-シス-D-ヒドロキシプロリンを異なる混合比率で調製した混合液を用いて、細胞増殖及びメラニン量の低減試験を実施した。細胞培養、定量及び評価は上記実施例と同様に行なった。
図3(ハッチング入りの棒)にさまざまな濃度で4-トランス-L-ヒドロキシプロリンと、4-シス-D-ヒドロキシプロリンと、前記混合液とを添加したマウスB16メラノーマ細胞の細胞増殖を調べた実験結果を示す。各実験条件の誤差棒は同一条件で2回繰り返した実験結果の測定値の標準偏差を示す。図3Aは、さまざまな濃度で4-トランス-L-ヒドロキシプロリンを添加した後のコントロールを100%としたときの細胞数を示し、333ppmで100%、480ppmで96%、666ppmで102%及び1332ppmで99%であった。図3Bは、さまざまな濃度で4-シス-D-ヒドロキシプロリンを添加した後のコントロールを100%としたときの細胞数を示し、33.3ppmで93%、50ppmで92%、100ppmで91%及び333ppmで88%であった。図3Cは、さまざまな濃度で4-トランス-L-ヒドロキシプロリン及び4-シス-D-ヒドロキシプロリンの異なる混合比率の混合液(4-シス-D:4-トランス-L)を添加した後のコントロールを100%としたときの細胞数を示し、333ppm:333pmで98%、333ppm:480ppmで99%、333ppm:666ppmで100%及び333ppm:1332ppmで98%であり、4-シス-D-ヒドロキシプロリン及び4-トランス-L-ヒドロキシプロリンの混合液の添加は、対照と同様のコントロールを100%としたときの細胞数を示した。
図3(黒塗りの棒)にさまざまな濃度で4-トランス-L-ヒドロキシプロリンと、4-シス-D-ヒドロキシプロリンと、前記混合液とを添加したマウスB16メラノーマ細胞のメラニン量低減能を調べた実験結果の測定値を示す。各実験条件の誤差棒は同一条件で2回繰り返した実験結果の測定値の標準偏差を示す。図3Aは、さまざまな濃度で4-トランス-L-ヒドロキシプロリンを添加した後のメラニン量率を示し、333ppmで103%、480ppmで99%、666ppmで107%及び1332ppmで102%であった。図3Bは、さまざまな濃度で4-シス-D-ヒドロキシプロリンを添加した後のメラニン量率を示し、33.3ppmで92%、50ppmで84%、100ppmで75%及び333ppmで37%であった。図3Cは、さまざまな濃度で4-トランス-L-ヒドロキシプロリン及び4-シス-D-ヒドロキシプロリンの異なる混合比率の混合液(4-シス-D:4-トランス-L)を添加した後のメラニン量率を示し、333ppm:333pmで62%、333ppm:480ppmで66%、333ppm:666ppmで72%及び333ppm:1332ppmで69%であった。以上の結果から、4-シス-D-ヒドロキシプロリン及び4-トランス-L-ヒドロキシプロリンの混合液の添加は、4-シス-D-ヒドロキシプロリンを単独で添加した際に示す濃度依存的なメラニン量の抑制を阻害することが示された。しかし、4-シス-D-ヒドロキシプロリンに対する4-トランス-L-ヒドロキシプロリンの濃度を高くしても、メラニン量の抑制を著しく抑制することはなかった。
(組成物) 配合量(重量%)
4-シス-ヒドロキシプロリン 0.42
ベヘニルアルコール 0.2
セタノール 0.5
グリセリンモノ脂肪酸エステル 1.8
硬化ヒマシ油POE(60) 1.0
白色ワセリン 2.0
流動パラフィン 10.0
ミリスチン酸イソプロピル 3.0
メチルポリシロキサン(6cs) 1.5
濃グリセリン 13.0
ジプロピレングリコール 2.0
カルボキシビニルポリマー 0.25
ヒアルロン酸ナトリウム 0.005
水酸化カリウム 適量
乳酸 適量
エデト酸ナトリウム 適量
エチルパラベン 適量
精製水 残余
100.000
(組成物) 配合量(重量%)
4-シス-ヒドロキシプロリン 0.3
ポリアクリル酸 3.0
ポリアクリル酸ナトリウム 2.5
ゼラチン 0.5
カルボキシメチルセルロースナトリウム 4.0
ポリビニルアルコール 0.3
濃グリセリン 14.0
1,3-ブチレングリコール 12.0
水酸化アルミニウム 0.1
エデト酸ナトリウム 0.03
メチルパラベン 0.1
精製水 残余
100.00
(組成物) 配合量(mg/1錠中)
4-シス-ヒドロキシプロリン 360.5
乳糖 102.4
カルボキシメチルセルロースカルシウム 29.9
ヒドロキシプロピルセルロース 6.8
ステアリン酸マグネシウム 5.2
結晶セルロース 10.2
515.0
(組成物) 配合量(mg/1錠中)
ショ糖エステル 70
結晶セルロース 74
メチルセルロース 36
グリセリン 25
4-シス-ヒドロキシプロリン 475
N-アセチルグルコサミン 200
ヒアルロン酸 150
ビタミンE 30
ビタミンB6 20
ビタミンB2 10
α-リポ酸 20
コエンザイムQ10 40
セラミド(コンニャク抽出物) 50
L-プロリン 300
1500
(組成物) 配合量(mg/1カプセル中)
食用大豆油 530
トチュウエキス 50
ニンジンエキス 50
4-シス-ヒドロキシプロリン 100
ローヤルゼリー 50
マカ 30
GABA 30
ミツロウ 60
ゼラチン 375
グリセリン 120
グリセリン脂肪酸エステル 105
1500
(組成物) 配合量(mg/1カプセル中)
玄米胚芽油 659
4-シス-ヒドロキシプロリン 500
レスベラトロール 1
ハス胚芽エキス 100
エラスチン 180
DNA 30
葉酸 30
1500
(組成物) 配合量(mg/1包中)
4-シス-ヒドロキシプロリン 400
ビタミンC 100
大豆イソフラボン 250
還元乳糖 300
大豆オリゴ糖 36
エリスリトール 36
デキストリン 30
香料 24
クエン酸 24
1200
(組成物) 配合量(g/60mL中)
トチュウエキス 1.6
ニンジンエキス 1.6
4-シス-ヒドロキシプロリン 1.6
還元麦芽糖水飴 28
エリスリトール 8
クエン酸 2
香料 1.3
N-アセチルグルコサミン 1
ヒアルロン酸Na 0.5
ビタミンE 0.3
ビタミンB6 0.2
ビタミンB2 0.1
α-リポ酸 0.2
コエンザイムQ10 1.2
セラミド(コンニャク抽出物) 0.4
L-プロリン 2
精製水 残余
60
(組成物) 配合量(重量%)
砂糖 50
水飴 48
4-シス-ヒドロキシプロリン 1
香料 1
100
(組成物) 配合量(重量%)
薄力粉 45.0
バター 17.5
グラニュー糖 20.0
4-シス-ヒドロキシプロリン 4.0
卵 12.5
香料 1.0
100.0
バターを撹拌しながらグラニュー糖を徐々に添加し、卵、デカペプチド、GABA及び香料を添加して撹拌した。十分に混合した後、均一に振るった薄力粉を加えて低速で撹拌し、塊状で冷蔵庫で寝かせた。その後、成型し170°C15分間焼成しクッキーとした。
(組成物) 配合量(g)
大豆 1000
米麹 1000
塩 420
4-シス-ヒドロキシプロリン 158
水 残余
4000
米こうじと塩とをよく混ぜ合わせる。洗浄した大豆を3倍量の水に一晩つけた後に水を切り、新しい水を加えながら煮込み、ざるにあける。煮汁(種水)を集め、4-シス-ヒドロキシプロリンを10%w/vとなるように溶解する。煮あがった豆を直ちにすりつぶし、塩を混ぜた米麹を加えて、上記の4-シス-ヒドロキシプロリンを溶解した種水を足しながら粘土程の固さになるまでむらなく混ぜ合わせる。団子状に丸めたものを桶に隙間のない様に隅々まで、しっかりと詰め込み、表面を平らにしてラップで覆い密封する。3箇月後に容器を移し変え、表面を平らにしてラップで覆う。なお、4-シス-ヒドロキシプロリンを種水に加える代わりに、4-シス-ヒドロキシプロリンを多く産生する米麹を用いてもよい。また、市販の味噌に4-シス-ヒドロキシプロリンか、あるいはその塩を加えてもよい。
(組成物) 配合量(g)
サラダ油 27.0
酢 30.0
塩化ナトリウム 0.9
4-シス-ヒドロキシプロリン 1.1
胡椒 1.0
60.0
酢に塩化ナトリウム及び4-シス-ヒドロキシプロリンを加えた後に、よく攪拌して溶解する。サラダ油を加えて、よく攪拌し胡椒を加える。
(組成物) 配合量(g)
サラダ油 134.0
酢 5
塩化ナトリウム 0.9
4-シス-ヒドロキシプロリン 1
卵黄 18
砂糖 0.2
胡椒 0.9
160.0
卵黄(室温)に酢、塩化ナトリウム、4-シス-ヒドロキシプロリンと、胡椒とを加えて、泡立て器で十分に攪拌する。サラダ油を少しずつ加えながら攪拌を継続してエマルジョンにする。最後に砂糖を加えて攪拌する。
(組成物) 配合量(g)
強力粉 140
薄力粉 60
塩化ナトリウム 3
砂糖 6
4-シス-ヒドロキシプロリン 2
ドライイースト 4
ぬるま湯 128
343
ぬるま湯に砂糖1g及びドライイーストを入れて予備発酵させる。強力粉、薄力粉、塩化ナトリウム及び砂糖5gと、4-シス-ヒドロキシプロリンとをボウルに入れ、その中に予備発酵させたイーストを入れる。十分捏ねた後に球状にして30°Cで一次発酵させる。生地を再度捏ねてから休ませた後に適当な形に整形して電子発酵機を用いて最終発酵させる。クープを入れて220°Cのオーブンで30分間焼く。
(組成物) 配合量(g)
市販の醤油 990
4-シス-ヒドロキシプロリン 10
1000
市販の醤油に4-シス-ヒドロキシプロリンを加えてよく攪拌する。また、4-シス-ヒドロキシプロリンか、あるいはその塩を加える代わりに、4-シス-ヒドロキシプロリンを多く産生する麹を用いて醤油を醸造してもよい。
(組成物) 配合量(g)
牛乳 880
L.ブルガリカス菌 50
S.サーモフィルス菌 50
4-シス-ヒドロキシプロリン 20
1000
40°C~45°Cで発酵させる。他の市販の種菌を用いてもよく、市販のヨーグルトに4-シス-ヒドロキシプロリンを加えてもよい。また、4-シス-ヒドロキシプロリンか、あるいはその塩を加える代わりに、4-シス-ヒドロキシプロリンを多く産生する菌を用いてもよい。
(組成物) 配合量(g)
4-シス-ヒドロキシプロリン 50
のり 15
L-グルタミン酸Na 10
塩化ナトリウム 2
煎りごま 10
さば削り節 10
砂糖 1
醤油 2
100
(組成物) 配合量(g)
市販の納豆のたれ 9.9
4-シス-ヒドロキシプロリン 0.1
10
(組成物) 配合量(g)
市販の納豆 19.9
4-シス-ヒドロキシプロリン 0.1
20
4-シス-ヒドロキシプロリンか、あるいはその塩を加える代わりに、4-シス-D-ヒドロキシプロリンを多く産生する菌を用いて納豆を作ってもよい。
(組成物) 配合量(g)
市販のもろみ黒酢 950
4-シス-ヒドロキシプロリン 50
1000
4-シス-ヒドロキシプロリンか、あるいはその塩を加える代わりに、4-シス-ヒドロキシプロリンを多く産生する菌を用いて酢、黒酢、もろみを作ってもよい。
(組成物) 配合量(%)
流動パラフィン 3
ワセリン 1
ジメチルポリシロキサン 1
ステアリルアルコール 1.8
ベヘニルアルコール 1.6
グリセリン 8
ジプロピレングリコール 5
マカデミアナッツ油 2
硬化油 3
スクワラン 6
ステアリン酸 2
ヒドロキシステアリン酸コレステリル 0.5
2-エチルヘキサン酸セチル 4
ポリオキシエチレン硬化ヒマシ油 0.5
自己乳化型モノステアリン酸グリセリン 3
水酸化カリウム 0.15
ヘキサメタリン酸ナトリウム 0.05
トリメチルグリシン 2
α-トコフェロール 2-L-アスコルビン酸
リン酸ジエステルカリウム 1
酢酸トコフェロール 0.1
4-シス-ヒドロキシプロリン 4
パラベン 適量
エデト酸3ナトリウム 0.05
4-t-ブチル-4’-メトキシジベンゾイルメタン 0.05
ジパラメトキシ桂皮酸モノ-2-エチルヘキサン酸グリセリル 0.05
色剤 適量
カルボキシビニルポリマー 0.05
精製水 残余
100.00
(組成物) 配合量(%)
ジメチルポリシロキサン 3
デカメチルシクロペンタシロキサン 13
ドデカメチルシクロヘキサシロキサン 12
ポリオキシエチレン・メチルポリシロキサン共重合体 1
エタノール 2
イソプロパノール 1
グリセリン 3
ジプロピレングリコール 5
ポリエチレングリコール6000 5
ヘキサメタリン酸ナトリウム 0.05
酢酸トコフェロール 0.1
4-シス-ヒドロキシプロリン 5
ウイキョウエキス 0.1
ハマメリスエキス 0.1
ニンジンエキス 0.1
L-メントール 適量
パラオキシ安息香酸エステル 適量
エデト酸三ナトリウム 0.05
ジモルホリノピリダジノン 0.01
トリメトキシ桂皮酸メチルビス(トリメチルシロキシ)
シリルイソペンチル 0.1
黄酸化鉄 適量
チタン酸コバルト 適量
ジメチルジステアリルアンモニウムヘクトライト 1.5
ポリビニルアルコール 0.1
ヒドロキシエチルセルロース 0.1
トリメチルシロキシケイ酸 2
香料 適量
精製水 残余
100.00
(組成物) 配合量(%)
ジメチルポリシロキサン 5
グリセリン 2
1,3-ブチレングリコール 5
ポリエチレングリコール1500 3
ポリエチレングリコール20000 3
オクタン酸セチル 3
クエン酸 0.01
クエン酸ナトリウム 0.1
ヘキサメタリン酸ナトリウム 0.1
グリチルリチン酸ジカリウム 0.1
4-シス-ヒドロキシプロリン 2
酢酸トコフェロール 0.1
オウゴンエキス 0.1
ユキノシタエキス 0.1
エデト酸三ナトリウム 0.1
キサンタンガム 0.3
アクリル酸・メタクリル酸アルキル共重合体(ペミュレンTR-2)
0.05
寒天末 1.5
フェノキシエタノール 適量
ジブチルヒドロキシトルエン 適量
精製水 残余
100.00
(組成物) 配合量(%)
エタノール 10
1,3-ブチレングリコール 6
ポリエチレングリコール4000 2
オリーブ油 1
マカデミアナッツ油 1
ヒドロキシステアリン酸フィトステリル 0.05
乳酸 0.05
乳酸ナトリウム 0.1
L-アスコルビン酸硫酸エステル2ナトリウム 0.1
α-トコフェロール 2-L-アスコルビン酸
リン酸ジエステルカリウム 0.1
4-シス-ヒドロキシプロリン 10
魚コラーゲン 0.1
コンドロイチン硫酸トリウム 0.1
カルボキシメチルセルロースナトリウム 0.2
ポリビニルアルコール 12
パラオキシ安息香酸エステル 適量
香料 適量
精製水 残余
100.00
(組成物) 配合量(%)
グリセリン 1
1,3-ブチレングリコール 8
キシリット 2
ポリエチレングリコール1500 2
ローズマリー油 0.01
セージ油 0.1
クエン酸 0.02
クエン酸ナトリウム 0.08
ヘキサメタリン酸ナトリウム 0.01
ヒドロキシプロピル-β-シクロデキストリン 0.1
4-シス-ヒドロキシプロリン 0.5
バーチエキス 0.1
ラベンダー油 0.01
キサンタンガム 0.05
カルボキシビニルポリマー 0.15
パラオキシ安息香酸エステル 適量
精製水 残余
100.00
(組成物) 配合量(%)
流動パラフィン 7
ワセリン 3
デカメチルシクロペンタシロキサン 2
ベヘニルアルコール 1.5
グリセリン 5
ジプロピレングリコール 7
ポリエチレングリコール1500 2
ホホバ油 1
イソステアリン酸 0.5
ステアリン酸 0.5
ベヘニン酸 0.5
テトラ2-エチルヘキサン酸ペンタエリスリット 3
2-エチルヘキサン酸セチル 3
モノステアリン酸グリセリン 1
モノステアリン酸ポリオキシエチレングリセリン 1
水酸化カリウム 0.1
ヘキサメタリン酸ナトリウム 0.05
グリチルレチン酸ステアリル 0.05
4-シス-ヒドロキシプロリン 1
ローヤルゼリーエキス 0.1
酵母エキス 0.1
酢酸トコフェロール 0.1
アセチル化ヒアルロン酸ナトリウム 0.1
エデト酸三ナトリウム 0.05
4-t-ブチル-4’-メトキシジベンゾイルメタン 0.1
パラメトキシ桂皮酸2-エチルヘキシル 0.1
カルボキシビニルポリマー 0.15
パラベン 適量
香料 適量
精製水 残余
100.00
(組成物) 配合量(%)
ジメチルポリシロキサン 2
ベヘニルアルコール 1
バチルアルコール 0.5
グリセリン 5
1,3-ブチレングリコール 7
エリスリトール 2
硬化油 3
スクワラン 6
テトラ2-エチルヘキサン酸ペンタエリスリット 2
イソステアリン酸ポリオキシエチレングリセリル 1
モノステアリン酸ポリオキシエチレングリセリン 1
4-シス-ヒドロキシプロリン 0.3
水酸化カリウム 適量
ヘキサメタリン酸ナトリウム 0.05
フェノキシエタノール 適量
カルボキシビニルポリマー 0.1
精製水 残余
100.00
(組成物) 配合量(%)
エチルアルコール 5
グリセリン 1
1,3-ブチレングリコール 5
ポリオキシエチレンポリオキシプロピレン
デシルテトラデシルエーテル 0.2
ヘキサメタリン酸ナトリウム 0.03
トリメチルグリシン 1
ポリアスパラギン酸ナトリウム 0.1
α-トコフェロール 2-L-アスコルビン酸
リン酸ジエステルカリウム 0.1
チオタウリン 0.1
4-シス-ヒドロキシプロリン 8
EDTA3ナトリウム 0.1
カルボキシビニルポリマー 0.05
水酸化カリウム 0.02
フェノキシエタノール 適量
香料 適量
精製水 残余
100.00
(組成物) 配合量(%)
エタノール 10
ジプロピレングリコール 1
ポリエチレングリコール1000 1
ポリオキシエチレンメチルグルコシド 1
ホホバ油 0.01
トリ2-エチルヘキサン酸グリセリル 0.1
ポリオキシエチレン硬化ヒマシ油 0.2
ジイソステアリン酸ポリグリセリル 0.15
N-ステアロイル-L-グルタミン酸ナトリウム 0.1
クエン酸 0.05
クエン酸ナトリウム 0.2
水酸化カリウム 0.4
グリチルリチン酸ジカリウム 0.1
塩酸アルギニン 0.1
L-アスコルビン酸 2-グルコシド 2
4-シス-ヒドロキシプロリン 0.5
エデト酸三ナトリウム 0.05
パラメトキシ桂皮酸2-エチルヘキシル 0.01
ジブチルヒドロキシトルエン 適量
パラベン 適量
海洋深層水 3
香料 適量
精製水 残余
100.00
(組成物) 配合量(重量%)
エタノール 15.0
ポリオキシエチレン硬化ヒマシ油50 1.5
ジフェンヒドラミン 1.0
ジブカイン 2.0
酢酸トコフェロール 0.5
4-シス-ヒドロキシプロリン 0.1
イソステアリン酸 0.1
1,3-ブチレングリコール 3.0
ポリエチレングリコール400 3.0
カンフル 0.05
尿素 20.0
精製水 残余
100.00
(組成物) 配合量(重量%)
エアゾール尿素外用剤原液 65.0
ジメチルエーテル 35.0
100.00
エアゾール尿素外用剤原液及びジメチルエーテルを内面テフロン(登録商標)コート処理耐圧エアゾールアルミ缶に充填してエアゾール剤を調製する。
Claims (11)
- 4-シス-ヒドロキシプロリンと、その誘導体及び/又は塩とからなる群から選択される1種類又は2種類以上の化合物を含むことを特徴とする、美白剤。
- 前記4-シス-ヒドロキシプロリンは4-シス-L-ヒドロキシプロリンであることを特徴とする、請求項1に記載の美白剤。
- 前記4-シス-ヒドロキシプロリンは4-シス-D-ヒドロキシプロリンであることを特徴とする、請求項1に記載の美白剤。
- 経口投与剤であることを特徴とする、請求項1ないし3に記載の美白剤。
- 請求項1ないし3のいずれか1つに記載の美白剤を含むことを特徴とする、美白用皮膚外用組成物。
- 請求項1ないし3のいずれか1つに記載の美白剤を含むことを特徴とする、食品組成物。
- 請求項1ないし3のいずれか1つに記載の美白剤を含むことを特徴とする、医薬品組成物。
- 4-シス-ヒドロキシプロリンと、その誘導体及び/又は塩とからなる群から選択される1種類又は2種類以上の化合物を含むことを特徴とする、皮膚外用組成物。
- 4-シス-ヒドロキシプロリンと、その誘導体及び/又は塩とからなる群から選択される1種類又は2種類以上の化合物を投与するステップを含むことを特徴とする、皮膚を美白にする美容方法。
- 前記4-シス-ヒドロキシプロリンは4-シス-L-ヒドロキシプロリンであることを特徴とする、請求項9に記載の方法。
- 前記4-シス-ヒドロキシプロリンは4-シス-D-ヒドロキシプロリンであることを特徴とする、請求項9に記載の方法。
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2011143735/15A RU2011143735A (ru) | 2009-03-31 | 2010-03-04 | Средство для отбеливания кожи и косметический способ отбеливания кожи |
BRPI1010289A BRPI1010289A2 (pt) | 2009-03-31 | 2010-03-04 | agente de clareamento da pele e método cosmético para o clareamento da pele |
EP10758366A EP2415453A4 (en) | 2009-03-31 | 2010-03-04 | SKIN-HELLENDER AND COSMETIC SKIN-ILLUMINATION PROCESS |
US13/138,787 US20120122951A1 (en) | 2009-03-31 | 2010-03-04 | Skin-whitening agent and cosmetic method for whitening skin |
JP2011507069A JPWO2010113590A1 (ja) | 2009-03-31 | 2010-03-04 | 美白剤及び皮膚を美白にする美容方法 |
AU2010230922A AU2010230922A1 (en) | 2009-03-31 | 2010-03-04 | Skin-whitening agent and cosmetic method for whitening skin |
CN2010800148600A CN102378622A (zh) | 2009-03-31 | 2010-03-04 | 美白剂及使皮肤美白的美容方法 |
TW099108550A TW201100108A (en) | 2009-03-31 | 2010-03-23 | Skin-whitening agent and cosmetic method for whitening skin |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009088222 | 2009-03-31 | ||
JP2009-088222 | 2009-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010113590A1 true WO2010113590A1 (ja) | 2010-10-07 |
Family
ID=42827891
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2010/053569 WO2010113590A1 (ja) | 2009-03-31 | 2010-03-04 | 美白剤及び皮膚を美白にする美容方法 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20120122951A1 (ja) |
EP (1) | EP2415453A4 (ja) |
JP (1) | JPWO2010113590A1 (ja) |
KR (1) | KR20110136868A (ja) |
CN (1) | CN102378622A (ja) |
AU (1) | AU2010230922A1 (ja) |
BR (1) | BRPI1010289A2 (ja) |
RU (1) | RU2011143735A (ja) |
TW (1) | TW201100108A (ja) |
WO (1) | WO2010113590A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106176464A (zh) * | 2016-08-31 | 2016-12-07 | 南京禾宇化工有限公司 | 一种玫瑰花露颈部精华液的制造方法 |
KR102203722B1 (ko) * | 2018-06-18 | 2021-01-15 | 주식회사 인코스팜 | 신규한 화합물, 이를 포함하는 화장료 조성물 및 약학적 조성물 |
CN113115876A (zh) * | 2021-04-28 | 2021-07-16 | 北京逯博士行为医学科技研究院有限公司 | 一种用于健肤强体的美白组合物 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000051561A1 (fr) * | 1999-03-02 | 2000-09-08 | Kyowa Hakko Kogyo Co., Ltd. | Produits cosmetiques |
JP2004315384A (ja) * | 2003-04-14 | 2004-11-11 | Kyowa Hakko Kogyo Co Ltd | 美白剤 |
US6852747B2 (en) | 2000-09-11 | 2005-02-08 | Pfizer Inc. | Resorcinol derivatives |
US20090023792A1 (en) | 2000-02-29 | 2009-01-22 | Mediquest Therapeutics, Inc. | Inhibitors of melanocyte tyrosinase as topical skin lighteners |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1054505C (zh) * | 1996-12-11 | 2000-07-19 | 林镇才 | 一种活性成份的化妆品添加剂 |
-
2010
- 2010-03-04 RU RU2011143735/15A patent/RU2011143735A/ru unknown
- 2010-03-04 CN CN2010800148600A patent/CN102378622A/zh active Pending
- 2010-03-04 WO PCT/JP2010/053569 patent/WO2010113590A1/ja active Application Filing
- 2010-03-04 JP JP2011507069A patent/JPWO2010113590A1/ja not_active Withdrawn
- 2010-03-04 US US13/138,787 patent/US20120122951A1/en not_active Abandoned
- 2010-03-04 EP EP10758366A patent/EP2415453A4/en not_active Withdrawn
- 2010-03-04 AU AU2010230922A patent/AU2010230922A1/en not_active Abandoned
- 2010-03-04 KR KR1020117024675A patent/KR20110136868A/ko not_active Application Discontinuation
- 2010-03-04 BR BRPI1010289A patent/BRPI1010289A2/pt not_active Application Discontinuation
- 2010-03-23 TW TW099108550A patent/TW201100108A/zh unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000051561A1 (fr) * | 1999-03-02 | 2000-09-08 | Kyowa Hakko Kogyo Co., Ltd. | Produits cosmetiques |
US20090023792A1 (en) | 2000-02-29 | 2009-01-22 | Mediquest Therapeutics, Inc. | Inhibitors of melanocyte tyrosinase as topical skin lighteners |
US6852747B2 (en) | 2000-09-11 | 2005-02-08 | Pfizer Inc. | Resorcinol derivatives |
JP2004315384A (ja) * | 2003-04-14 | 2004-11-11 | Kyowa Hakko Kogyo Co Ltd | 美白剤 |
Non-Patent Citations (5)
Title |
---|
BIOCHEM. PHARMACOL., vol. 57, 1999, pages 663 - 672 |
JAPAN COSMETIC INDUSTRY ASSOCIATION, NIPPON KESHOHIN SEIBUN HYOJI MEISHO JITEN, 27 April 2001 (2001-04-27), pages 396 * |
MUTAGENESIS, vol. 5, 1990, pages 263 - 266 |
R.A. JUDE ET AL.: "Cis-Hydroxyproline Influence on Protein Synthesis and Growth in Melanoma Cells.", JOURNAL OF DENTAL RESEARCH, vol. 66, 1987, pages 159, XP008047846 * |
See also references of EP2415453A4 * |
Also Published As
Publication number | Publication date |
---|---|
EP2415453A4 (en) | 2012-07-25 |
CN102378622A (zh) | 2012-03-14 |
RU2011143735A (ru) | 2013-05-10 |
AU2010230922A1 (en) | 2011-11-10 |
BRPI1010289A2 (pt) | 2016-03-22 |
KR20110136868A (ko) | 2011-12-21 |
TW201100108A (en) | 2011-01-01 |
EP2415453A1 (en) | 2012-02-08 |
JPWO2010113590A1 (ja) | 2012-10-11 |
US20120122951A1 (en) | 2012-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6023428B2 (ja) | ラミニン332産生促進組成物 | |
EP2484340B1 (en) | Collagen production accelerating composition | |
JP5934405B2 (ja) | 紫外線障害軽減組成物 | |
JP5795960B2 (ja) | 紫外線障害軽減組成物 | |
JP6018752B2 (ja) | 抗酸化組成物 | |
WO2010113590A1 (ja) | 美白剤及び皮膚を美白にする美容方法 | |
JP2014031323A (ja) | セラミド産生促進用組成物 | |
WO2012043185A1 (ja) | Il-8発現抑制組成物 | |
WO2013128736A1 (ja) | 紫外線曝露によって促進される血管新生を抑制するための組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080014860.0 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10758366 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011507069 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2180/MUMNP/2011 Country of ref document: IN Ref document number: 2010758366 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20117024675 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2011143735 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2010230922 Country of ref document: AU Date of ref document: 20100304 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13138787 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: PI1010289 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: PI1010289 Country of ref document: BR Kind code of ref document: A2 Effective date: 20110927 |